Money
Filter News
Found 84,529 articles
-
Stoke Therapeutics plans to offer up more than 5.5 million shares of its common stock following positive Phase I/IIa data for its Dravet syndrome candidate.
-
Continuing 2024’s biotech initial public offering rally, Boundless Bio will debut Thursday on the Nasdaq with the proceeds used to advance its pipeline of extrachromosomal DNA cancer assets.
-
Follow along as BioSpace keeps you up to date on the latest pharma and biotech M&As, from announcements to closings.
-
Praxis Precision Medicines, Inc. Announces Pricing of $200 Million Public Offering - March 28, 2024
3/28/2024
Praxis Precision Medicines, Inc. announced the pricing of its underwritten public offering of 3,318,585 shares of its common stock at a public offering price per share of $56.50 and, in lieu of shares of common stock, pre-funded warrants to purchase up to an aggregate of 221,238 shares of common stock at a purchase price of $56.4999 per pre-funded warrant, which equals the public offering price per share of the common stock less the $0.0001 per share exercise price of each pre-funded warrant.
-
Stoke Therapeutics Announces Pricing of Upsized $125 Million Public Offering
3/28/2024
Stoke Therapeutics, Inc. announced the pricing of its upsized underwritten public offering of 5,555,557 shares of its common stock at a price to the public of $13.50 per share and, in lieu of common stock to investors that so choose, pre-funded warrants to purchase up to an aggregate of 3,703,730 shares of its common stock at a price to the public of $13.4999.
-
Tigermed Reports Full Year 2023 Results
3/28/2024
Hangzhou Tigermed Consulting Co., Ltd., a leading global provider of integrated research and development solutions for biopharmaceutical and medical device industry, announced its annual results for the year ended December 31, 2023.
-
Erasca Announces $45 Million Oversubscribed Private Placement Financing
3/28/2024
Erasca, Inc. announced that it has entered into a securities purchase agreement with a select group of institutional accredited investors to sell 21,844,660 shares of its common stock in an oversubscribed private placement at a price of $2.06 per share.
-
China Medical System (867.HK)2023 Annual Results: Despite of the Temporary Financial Performance Pressure Fresh Catalysts Emerged from Successive Innovation Breakthroughs
3/28/2024
On March 27, 2024, China Medical System released its 2023 annual results. The Company recorded a turnover of RMB8,013 million, a year-on-year decrease of 12.4%; in the case that all medicines were directly sold by the Group, the turnover would be RMB 9,472 million, a year-on-year decrease of 9.8%.
-
Kodiak Sciences Announces Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results
3/28/2024
Kodiak Sciences Inc., reported business highlights and financial results for the quarter and year ended December 31, 2023.
-
DarioHealth Reports Fourth Quarter and Full-Year 2023 Financial and Operating Results
3/28/2024
DarioHealth Corp., a leader in the global digital health market, reported financial results for the fourth quarter 2023 and the full year 2023 and provided a corporate and commercial update.
-
Sequana Medical announces 2023 Full Year Results and 2024 Outlook
3/28/2024
Sequana Medical NV, a pioneer in the treatment of fluid overload in liver disease, heart failure and cancer, announces its financial results for the year ended 31 December 2023, and provides a business update and outlook for 2024 and beyond.
-
Medigene AG Reports Full-Year 2023 Financial Results and Provides Corporate Update
3/28/2024
Medigene AG reported financial results for the fiscal year ended December 31, 2023, and provided a corporate update.
-
Avenzo Therapeutics on Tuesday said it will use the financing round to advance its next-generation oncology pipeline, including a potentially best-in-class CDK2 selective inhibitor.
-
Theralase(R) Release's 4Q2023 Interim Financial Statements
3/27/2024
Theralase® Technologies Inc., a clinical stage pharmaceutical company dedicated to the research and development of light and/or radiation activated Photo Dynamic Compounds for the safe and effective destruction of various cancers, bacteria and viruses has released the Company's audited annual consolidated 2023 financial statements.
-
Pluri Inc. Announces 1-for-8 Reverse Share Split
3/27/2024
Pluri Inc. announced that a reverse share split of the Company’s issued and outstanding common shares, par value $0.00001 per share at a ratio of 1-for-8 is expected to be implemented at market open on April 1, 2024.
-
Altimmune Announces Positive Lean Mass Preservation Data for Pemvidutide and Reports Fourth Quarter and Full Year 2023 Financial Results
3/27/2024
Altimmune, Inc., a clinical-stage biopharmaceutical company, announced financial results for the fourth quarter and full year ended December 31, 2023, and provided a business update.
-
EDAP Reports Fourth Quarter and Full-Year 2023 Financial Results
3/27/2024
EDAP TMS SA, the global leader in robotic energy-based therapies, reported unaudited financial results for the fourth quarter and full-year 2023.
-
Precision BioSciences Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Provides Business Update
3/27/2024
Precision BioSciences, Inc. announced financial results for the fourth quarter and fiscal year ended December 31, 2023 and provided a business update.
-
Merrimack Receives $225 Million Milestone Payment from Ipsen
3/27/2024
Merrimack Pharmaceuticals, Inc. announced that it has received a $225 million payment which was due from Ipsen, S.A. as a result of its receipt of approval from the U.S. Food and Drug Administration, or FDA, to market ONIVYDE as a first-line treatment of metastatic adenocarcinoma on the pancreas.
-
Vaccinex, Inc. Announces $1.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules
3/27/2024
Vaccinex, Inc. announced that it has entered into definitive agreements with certain institutional investors for the purchase and sale of 193,000 shares of its common stock in a registered direct offering together with warrants to purchase up to an aggregate of 193,000 shares of common stock in a concurrent private placement priced at-the-market under Nasdaq rules at a combined purchase price of $7.77 per share and accompanying warrant.